Publications
-
Porcel, JM; Salud, A; Nabal, M; Vives, M; Esquerda, A; Rodriguez-Panadero, F
Rapid pleurodesis with doxycycline through a small-bore catheter for the treatment of metastatic malignant effusions.
SUPPORTIVE CARE IN CANCER 14 475-478. .
-
Feliu, J; Salud, A; Escudero, P; Lopez-Gomez, L; Bolanos, M; Galan, A; Vicent, JM; Yubero, A; Losa, F; De Castro, J; de Mon, MA; Casado, E; Gonzalez-Baron, M; Oncopaz Cooperative Grp
XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer
BRITISH JOURNAL OF CANCER 94 969-975. .
-
Valentí Moreno V; Brunet Vidal J; Manzano Alemany H; Salud Salvia A; Llobera Serentill M; Cabezas Montero I; Servitja Tormo S; Sopena Bert E; Gumà Padró J
Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients.
CLINICAL & TRANSLATIONAL ONCOLOGY 8 208-212. .
-
Munoz, Alberto; Salud, Antonieta; Garcia Giron, Carlos; Murias, Adolfo; Burillo, Miguel A.; Arizcun, Alberto; Gutierrez, David; Pujol, Eduardo
Randomised phase III trial comparing irinotecan plus capecitabine (XELIRI Regimen) vs. irinotecan, 5-Fu and folinic acid (Saltz regimen) as first-line treatment in patients (PTS) with metastatic colorectal cancer (MCRC)
ANNALS OF ONCOLOGY 17 120-120. .
-
Escudero, Pilar; Alonso, Vicente; Salud, Antonieta; Lambea, Julio; Valencia, Javier; Mira, Moises; Polo, Sonia; Lao, Juan; Sierra, E.; Anton, Antonio
Preoperative radiochemotherapy with oxaliplatin and capecitabine in resectable rectal carcinoma: Preliminary results
ANNALS OF ONCOLOGY 17 285-285. .
-
Feliu, J; Castanon, C; Salud, A; Mel, JR; Escudero, P; Pelegrin, A; Lopez-Gomez, L; Ruiz, M; Gonzalez, E; Juarez, F; Lizon, J; Castro, J; Gonzalez-Baron, M; Oncopaz Cooperative Grp
Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer
BRITISH JOURNAL OF CANCER 93 1230-1235. .
-
Porcel, JM; Salud, A; Vives, M; Esquerda, A; Rodriguez-Panadero, F
Soluble oncoprotein 185HER-2 in pleural fluid has limited usefulness for the diagnostic evaluation of malignant effusions.
CLINICAL BIOCHEMISTRY 38 1031-1033. .
-
Salud, A.; Escudero, P.; Feliu, J.; Lopez-Gomez, L.; Bolanos, M.; Galan, A.; Yubero, A.; Vicent, J. M.; Losa, F.; Gonzalez-Baron, M.
Capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC)
Ejc Supplements 3 190-190. .
-
Nogue, M; Salud, A; Batiste-Alentorn, E; Saigi, E; Losa, F; Cirera, L; Mendez, M; Campos, JM; Galan, A; Escudero, P; Arcusa, A; Manzano, H; de Mendizabal, EV; de Olaguer, JP; Boleda, M; Guasch, I; Vicente, P
Randornised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer
EUROPEAN JOURNAL OF CANCER 41 2241-2249. .
-
Alonso, V; Salud, A; Escudero, P; Bueso, P; Mira, M; Valencia, J; Polo, S; de Lobera, AR; Lao, J; Lastra, R
Phase II trial of preoperative chemoradiotherapy with irinotecan and infusional 5-fluorouracil in locally advanced operable rectal carcinoma.
Journal of Clinical Oncology 23 256-256. .
-
Salud, A; Escudero, P; Feliu, J; Lopez-Gomez, L; Bolanos, M; Galan, A; Yubero, A; Vicent, JM; Losa, F; Baron, MG
XELOX (capecitabine and axaliplatin) as 1(st) line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC).
Journal of Clinical Oncology 23 276-276. .
-
Saigi, E; Batiste-Alentorn, E; Diaz, N; Galan, A; Salud, A; Campos, JM; Losa, F; Gallen, M; Massuti, B; Asensio, D
Phase II study of weekly irinotecan (CPT-11) associated to protracted oral tegafur (TGF) in previously untreated, advanced colorectal cancer (aCRC)
Journal of Clinical Oncology 23 302-302. .
Projects
- Ajuts per a la contractació de personal investigador novell (FI)
- Predicción de micrometástasis en pacientes con cáncer de colon localizado de alto riesgo
- Dimerizaciones de HER2 como elemento de decición en la terapia dirigida anti-HER2 frente al cáncer de mama
- UTILITAT PRONOSTICA DELS PERFILS D'EXPRESSIO PROTEICA EN PACIENTS AMB TUMOR RESIDUAL VIABLE (>1.0 CM) DESPRES DE LA QUIMIOTERAPIA NEOADJUVANT EN CANCER DE MAMA
- Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0 cm) tras quimioterapia neoadyuvante